High-dimensional investigation of the cerebrospinal fluid to explore and monitor CNS immune responses

Michael Heming, Anna-Lena Börsch, Heinz Wiendl and Gerd Meyer zu Hörste*

Abstract

The cerebrospinal fluid (CSF) features a unique immune cell composition and is in constant contact with the brain borders, thus permitting insights into the brain to diagnose and monitor diseases. Recently, the meninges, which are filled with CSF, were identified as a neuroimmunological interface, highlighting the potential of exploring central nervous system (CNS) immunity by studying CNS border compartments. Here, we summarize how single-cell transcriptomics of such border compartments advance our understanding of neurological diseases, the challenges that remain, and what opportunities novel multi-omic methods offer. Single-cell transcriptomics studies have detected cytotoxic CD4+ T cells and clonally expanded T and B cells in the CSF in the autoimmune disease multiple sclerosis; clonally expanded pathogenic CD8+ T cells were found in the CSF and in the brain adjacent to β-amyloid plaques of dementia patients; in patients with brain metastases, CD8+ T cell clonotypes were shared between the brain parenchyma and the CSF and persisted after therapy. We also outline how novel multi-omic approaches permit the simultaneous measurements of gene expression, chromatin accessibility, and protein in the same cells, which remain to be explored in the CSF. This calls for multicenter initiatives to create single-cell atlases, posing challenges in integrating patients and modalities across centers. While high-dimensional analyses of CSF cells are challenging, they hold potential for personalized medicine by better resolving heterogeneous diseases and stratifying patients.

Keywords  Cerebrospinal fluid, Single-cell transcriptomics, Multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, COVID-19, Brain metastases, Single-cell atlas

Background

The cerebrospinal fluid (CSF) is a clear liquid, an ultrafiltrate of the blood, ensheathing the central nervous system (CNS). Produced by the choroid plexus (CP) and ependymal cells in the brain ventricles, the CSF circulates to the subarachnoid space until being drained into the dural venous system through arachnoid villi [1]. Alternatively, the CSF flows directly into meningeal lymphatics [2, 3] or along cranial and spinal nerves into adjacent lymphatics [1]. There is also likely CSF influx into the brain parenchyma through periarterial spaces and efflux via paravenous spaces back into the subarachnoid space [4].

When diagnosing brain diseases, neurologists have to balance the potential benefit of correct and timely diagnosis against the risk of potentially invasive diagnostic procedures. A brain biopsy is often considered the “last resort” due to its potentially fatal complications (mortality 1–3.5% [5–7]). Studying CNS tissue is thus hampered by limited sample accessibility of human CNS tissue, which is even more rarely available for research purposes. This limits options for studying immune cells surrounding the human CNS to imaging approaches, rare biopsy/autopsy material, or analyzing CSF. Since the CSF...
is in constant contact with the brain borders, it facilitates insights into the brain and can be used to monitor CNS immune responses without the need for an invasive brain biopsy. In this review, we discuss how technological advances in single-cell sequencing have been used to understand CNS immunity in a variety of complex neurological diseases by characterizing CSF cells with unprecedented resolution.

**CSF—a unique immune tissue**

The CSF is a unique biomaterial both from a biological and medical point of view. The CSF bathes the brain, thus decreasing the weight of the brain by buoyancy from 1500 to 50 g [8]. Moreover, it provides trophic support for the CNS and controls lymphocyte and antigen shuttling from and towards the CNS parenchyma [3]. The volume of the CSF ranges between 125 and 150 ml in humans and a constant CSF production of approximately 25 ml/h results in complete CSF exchange of approximately four times per day [8]. Although the non-cellular fraction of the CSF is essentially a size-dependent ultrafiltrate of the blood, cells residing in the CSF are far from representing a mere “flow-over” of cells from the blood. Except for occasional ependymal debris or tumor cells, the cells found in the CSF are exclusively of hematopoietic origin, and therefore, the term CSF cells is generally and henceforth used synonymously to CSF leukocytes. However, CSF leukocytes are quantitatively and qualitatively disparate from blood leukocytes. The leukocyte concentration in the CSF is approximately 1000-fold lower than in the blood [9]. CD4+ T cells, in particular, activated central memory CD4+ T cells [10], dominate the healthy CSF, while myeloid-lineage cell numbers are low compared to blood [9, 10]. Using an unbiased single-cell transcriptomic approach, we recently characterized this CSF-specific cell composition with high resolution, identifying an increase of myeloid and plasmacytoid dendritic cells, CD4+ T cells, and regulatory T cells compared to blood. Inversely, B cells, plasma cells, granulocytes, NK cells, and monocyte subsets are reduced compared to blood [11]. In fact, CSF contains a monocyte subpopulation with a microglia-like phenotype [12–14], which is almost exclusive to the CSF [11]. This CSF microglia-like population was found to originate from the bone marrow in a single bone marrow transplant recipient patient [15], in contrast to resident microglia of the CNS, which derive from the yolk sac [16, 17]. Transcriptionally CSF T cells show enhanced expression of transcripts associated with migration (CD99), interaction with antigen-presenting cells (APC) (CD83, CD84) and chemokines (CXCL16, CXCR5), while genes associated with naive cell state (SELL), cytokine response (IL2RG), and integrins (ITGAL, VLA4) are reduced in CSF T cells compared to blood T cells [11]. The healthy CSF also contains clonally expanded T cells, which are presumably shared between blood and CSF [18]. In summary, the leukocyte composition and phenotype of CSF cells are distinct from the blood, indicating that the leukocyte composition and phenotype are tightly controlled by site-specific mechanisms [19].

**CSF—an important diagnostic tool**

To gain access to the CSF, a lumbar puncture (LP) can be performed quickly and at a relatively low risk [20] compared to a much more invasive brain biopsy. While the first reported LPs were performed already in the 19th century by Quincke and Essex [21], this technique still constitutes an essential diagnostic procedure in clinical neurology in most countries. However, in clinical neurology in most centers worldwide, CSF analysis remains limited to classification of CSF cells into basic hematopoietic lineages, quantification of protein, lactate, and glucose, calculating the CSF/serum quotient of albumin and immunoglobulins and testing for the synthesis of oligoclonal immunoglobulins in the CSF. Despite modern high-resolution imaging techniques, CSF analysis remains indispensable in clinical neurology in the diagnosis of common neurologic diseases, including meningitis, encephalitis leptomeningeal metastases, and small subarachnoid hemorrhage [22]. In multiple sclerosis (MS), the most common neuroinflammatory disorder of the CNS, the synthesis of oligoclonal immunoglobulins in the CSF has been included in the latest revision of the MS diagnostic criteria [23]. This shows that CSF analysis remains an important tool in modern clinical neurology. However, we believe that the potential of the CSF could be exploited to a far greater extent by performing higher-dimensional analyses of the CSF.

**Meninges and the CSF—neuroimmunological interface and gateway to the brain**

Improved understanding of the CSF is immediately interconnected with a better understanding of the meninges since these fibrous membranes are filled with CSF and wrap the brain (Fig. 1). The meninges consist of three layers: the outer dura mater, the arachnoid mater, and the pia mater with the CSF located in the subarachnoid space. While traditionally the meninges were considered as inert fibrous membranes solely providing mechanical protection to the brain, several recent studies redefined the meninges as a pivotal site of immune cell residence [24]. In fact, meningeal immune cells likely provide immunological protection against infections. In a recent study, IgA+ plasma cells were detected adjacent to dural venous sinuses, protecting the brain from infection by...
Fig. 1 High-dimensional analysis of the diseased CSF. A Schematic illustration of the brain parenchyma, the cerebrospinal fluid (CSF), the meninges, and the skull. Immune cells can migrate from the skull bone marrow through skull channels to the dura layer of the meninges, where they accumulate in the vicinity of dural sinuses. Main findings of single-cell transcriptomics studies of the CSF are visualized in the upper right, including cytotoxic T cells and clonal expansion of B and T cells in inflammatory diseases, cancer cells with iron-binding protein/protein and adhesion molecules in tumors, and clonally expanded T cell in neurodegenerative disorders (see Table 1 and main text for details). B Potential future applications. We envision that cell patterns and the transcriptomic profile of CSF single-cell analysis will be utilized in the future to train machine learning algorithms to predict the clinical outcome, support differential diagnosis and permit a personalized therapy.
entraping pathogens [25]. This provides evidence that meningeal immune cells are vital to maintaining CNS health. Shortly afterwards, we and others identified the meninges, and specifically, the dura, as an unexpected site of B cells and B cell progenitors that are usually not found outside the bone marrow [26–28]. The meninges also host myeloid cells that do not originate from the blood [29]. This indicates that meningeal immunity is not only important, but also developmentally and phenotypically unique. Both myeloid and B cell lineage might either develop directly in the meninges, mainly the dura [26], or derive from the skull bone marrow and migrate to the meninges through specialized skull channels [27, 29] (Fig. 1). The verdict is still out on whether the influx from skull bone marrow vs. local development model is correct and both hypotheses are not necessarily mutually exclusive. Collectively, these studies identified CNS border compartments, particularly meninges, as a novel neuroimmunological interface with various immune cell populations and thus need to be viewed in conjunction with CSF immune cells.

Besides studying immune cells in CNS-associated compartments, investigating the flux of CNS antigens is critical in order to better diagnose and treat neurological diseases because autoimmunity against CNS antigens can occur in multiple brain diseases. CNS antigen efflux occurs from the brain parenchyma via paravascular spaces through the CSF [4] to the perisinusoidal dura, where they are presented to patrolling T cells by dural antigen-presenting cells (APC) [3]. Dural sinuses thus may orchestrate immune surveillance of the brain [3]. CSF also enters the skull bone marrow, where it instructs local hematopoiesis [30]. These concepts have been translated to murine disease models. Autoreactive T cells that recognize myelin oligodendrocyte glycoprotein (MOG) are negatively selected in the meninges [28] and neuroinflammation induces an immune regulatory niche in local meningeal lymphatic vasculature [31]. Disruption of meningeal lymphatics diminishes MS [32], but deteriorates Alzheimer’s disease (AD) [33] in mouse models. Meningeal lymphatics exist also in humans as recent visualizations illustrate [34, 35]. In essence, a model emerges, in which the CSF, the meninges, and the overlying skull bone marrow might integrate into interconnected immunological barrier sites for the brain with protective functions in homeostasis and with negative effects when locally supporting autoimmunity [36]. Many aspects of this novel and partly hypothetical concept of a ‘peri-brain immune system’ are beginning to be resolved by using single-cell technologies.

Diseased CSF in the single-cell transcriptomics age—a new era

Single-cell RNA sequencing (scRNA-seq), method of the year in 2013 [37], has revolutionized many scientific fields, including neurology and neuroscience by enabling the dissection of cellular heterogeneity within complex tissues at an unprecedented resolution [38, 39]. There has been a recent ‘boom’ in translational scRNA-seq studies with relevance to clinical neurology [39, 40]. This is mainly due to a dramatic reduction of sequencing costs in combination with a commercially available microfluidics-based approach [41, 42], which allows the preparation of thousands of cells in one sample by using cell barcodes and unique molecular identifiers (UMIs), thus reducing cost and work time significantly. Due to its low input and immune cell heterogeneity, CSF is well suited for analysis by scRNA-seq [39]. In contrast to flow cytometry, scRNA-seq permits a hypothesis-free cell type identification with thousands of genes detected instead of a limited panel of antibodies of predefined markers. To establish an overview of scRNA-seq CSF studies, we provide a list of published single-cell transcriptomics studies of the CSF in Table 1. Main findings are depicted in Fig. 1 and we discuss the results and the implications for a more comprehensive and unbiased characterization of CNS immunity in complex neurological disorders in further detail in the following sections.

Dissecting immune responses in complex neuroinflammatory diseases by single-cell transcriptomics of the CSF

The paradigmatic neuroinflammatory disease MS has been most extensively studied via single-cell transcriptomics of the CSF (Table 1). A study of MS-discordant monozygotic twins detected clonally expanded CD8+ T cells in MS, but also in MS twins with subclinical neuroinflammation and in two autoimmune encephalitis (AIE) patients [43]. Plasmablasts were also identified in MS patients and MS-twins with subclinical neuroinflammation, while absent in healthy patients [43]. The findings imply that immune cell alterations precede the clinical manifestation of MS. The disease may thus be detectable preclinically by analyzing CSF leukocytes, and pathological immune alterations in preclinical stages could provide a rationale for early immunomodulating treatment. Our group described an increased proportion of B, plasma, NK, CD8+, CD4+ T cells, and follicular T helper cells (TFH) in the CSF of MS patients [11]. Such TFH cells accordingly exacerbated two animal models of MS [11, 36]. One cluster of CD4+ T cells showed a cytotoxic transcriptional phenotype, which is enriched among the effector memory recently activated pool of CD4+ T cells.
(CD4⁺ TEMRA) cells [44]. We confirmed that such CD4⁺ TEMRA cells expand in the CSF in MS [11]. A further scRNA-seq study also found clonally expanded B cells in the CSF of MS patients, that were transcriptionally associated with inflammation and blood-brain barrier breakdown, while no clonal expansion was observed in healthy patients [14]. At the same time, another group examined the CSF of MS patients and found an activated and cytotoxic phenotype of clonally expanded T cells [18]. However, the authors did not find an increase

| Category | Disease | Samples | Main findings | Reference |
|----------|---------|---------|---------------|-----------|
| **Inflammation** | MS | MS-affected twins: 4 CSF, 4 PBMC | Clonally expanded CD8⁺ T cells in the CSF of MS and SCNI, plasmablasts in the CSF of MS, SCNI, and AIE | [43] |
| AIE | MS, MS-affected twins: 4 CSF, 4 PBMC | Controls: 2 CSF, 2 PBMC | B/plasma cells, NK, CD8⁺/CD4⁺ T cells, THF in the CSF of MS, cytotoxic CD4⁺ TEMRA cells in the CSF of MS | [11] |
| OND | MS: 12 CSF, 12 PBMC | Controls: 3 CSF, 3 PBMC | Clonally expanded B cells associated with inflammation and blood-brain barrier breakdown in the CSF of MS | [14] |
| | MS | MS: 5 CSF, 5 PBMC | Activated and cytotoxic phenotype of clonally expanded T cells in the CSF of MS | [18] |
| IgG4-RD | IgG4-RD: 1 CSF | Controls: 6 CSF, 6 PBMC | CD8⁺ and CD4⁺ T cells, B cells in the CSF of IgG4-RD | [97] |
| MS | MS: 19 CSF | Controls: 2 CSF | Plasma cells and T cells in the CSF of MS | [15] |
| | MS | Controls: 3 CSF | Increase of myeloid cells and Reduction of B and T cells in anti-CD20 treated MS | [15] |
| **Degeneration** | AD | AD: 7 CSF | Clonally expanded CD8⁺ TEMRA cells in the CSF of AD | [30] |
| MCI | AD: 4 CSF | Controls: 14 CSF | TCRs similarity in the CSF of AD and MCI | [93] |
| PD | AD: 4 CSF | Controls: 14 CSF | TCRs similarity in the CSF of AD and MCI | [93] |
| MCI | AD: 7 CSF | Controls: 14 CSF | TCRs similarity in the CSF of AD and MCI | [93] |
| PD | AD: 7 CSF | Controls: 14 CSF | TCRs similarity in the CSF of AD and MCI | [93] |
| LBD | LBD: 11 CSF | Controls: 11 CSF | CXCR-expressing CD4⁺ T cells in the CSF of LBD | [52] |
| **Cancer** | BRCA | BRCA: 3 CSF | Iron-binding protein and its receptor expressed by cancer cells in the CSF | [54] |
| NSCLC | BRCA: 3 CSF | Controls: 3 CSF | Transcripts of cell adhesion and metabolic pathways in circulating tumor cells in the CSF | [55] |
| LUAD | LUAD: 4 CSF | Controls: 3 CSF | Identical TCR clones in the CSF and the brain in patients with brain metastasis | [57] |
| BRCA | LUAD: 4 CSF | Controls: 3 CSF | Identical TCR clones in the CSF and the brain in patients with brain metastasis | [57] |
| LUAD | ESCA: 2 CSF, 1 tumor | SKCM: SKCM, 1 CSF, 1 tumor | Increased dysfunctional T cells in the CSF from patients with leptomeningeal than with brain/skin metastases | [60] |
| ESCA | SKCM: SKCM, 1 CSF, 1 tumor | Controls: 11 CSF | Intratumor heterogeneity in the CSF of PCNSL | [59] |
| Melanoma | Melanoma: 18 CSF, 22 tumors | Control: 2 CSF | Increased dysfunctional T cells in the CSF from patients with leptomeningeal than with brain/skin metastases | [60] |
| **Infection** | HIV | HIV: 3 CSF | Microglia-like cells in the CSF of HIV | [13] |
| Control: 2 CSF | HIV: 3 CSF, 2 PBMC | Controls: 2 CSF | Exhausted CD8⁺ T cells and differentiated monocytes in the CSF of Neuro-COVID compared to VE | [61] |
| COVID-19 | Neuro-COVID: 8 CSF | Control: 6 CSF | Exhausted CD8⁺ T cells and differentiated monocytes in the CSF of Neuro-COVID compared to VE | [61] |
| VEE | Neuro-COVID: 8 CSF | Controls: 5 CSF | Exhausted CD8⁺ T cells and differentiated monocytes in the CSF of Neuro-COVID compared to VE | [61] |
| MS | COVID-19: 5 CSF, 6 PBMC | Controls: 6 CSF | T cell activation, clonal T cell expansion, B cell enrichment, and anti-neuronal autoantibodies in the CSF of COVID-19 | [62] |
| COVID-19 | COVID-19: 5 CSF, 6 PBMC | Controls: 6 CSF | T cell activation, clonal T cell expansion, B cell enrichment, and anti-neuronal autoantibodies in the CSF of COVID-19 | [62] |

Please note that in some cases the number of patients is ambiguous because samples were excluded for certain analyses or immune repertoire data was only available for a subset of patients. Reanalyzed samples, which were previously published, were not taken into account.

Abbreviations: AD Alzheimer’s disease, AIE autoimmune encephalitis, BRCA breast cancer, CSF cerebrospinal fluid, ESCA esophagus carcinoma, IgG4-RD IgG4-related disease, LBD Lewy body dementia, LUAD lung adenocarcinoma, MS multiple sclerosis, MCI mild cognitive impairment, NSCLC non-small cell lung cancer, NMOSD neuromyelitis optica spectrum disease, OND other neurological diseases, ONID other neuroinflammatory disorders, PD Parkinson’s disease, SCLC small cell lung cancer, SCNI subclinical neuroinflammation, scRNA-seq single-cell RNA sequencing, scTCR/BCR-seq single-cell T/B cell receptor sequencing, SKCM skin cutaneous melanoma, TEMRA, VE viral encephalitis.
of expanded T cells in MS compared to healthy and no clonal overlap between MS patients [18], in contrast to Beltran et al. [43]. The authors argue that this could be explained by T cells that migrate from the CSF to demyelinated lesions [18]. Additionally, the deviating findings might be due to the inherent heterogeneity of MS [45] and the small sample sizes. A recent preprint generated a large scRNA-seq CSF dataset of neuroinflammatory, mostly MS, and control patients [15]. Next to a reduction of microglia-like cells and the well-known expansion of plasma cells and T cells in the CSF of MS patients, the authors observed a reduction of B and T cells and an increase of myeloid cells of ocrelizumab (anti-CD20) treated progressive MS patients versus therapy-naive relapsing-remitting MS patients [15]. The authors speculate that a CD27 downregulation in plasma cells in ocrelizumab-treated MS patients might mediate the immunomodulatory effect of the therapy [15].

While these studies excel through their transcriptional resolution on a single-cell level, many studies lack methodical validation on the protein levels, although some [11, 14] provide flow cytometry verification. In addition, clinical validation cohorts would be preferable, but the technique yet remains prohibitively expensive. We find that the field would benefit from a meta-analytic integration of available single-cell datasets across tissues, centers, and neurological diseases to confirm or refute findings from individual studies with higher statistical power. Nonetheless, available data already demonstrate that high-dimensional scRNA-seq analyses of the CSF can successfully dissect complex neuroinflammatory diseases. Single-cell technologies will likely be extended to study the effect of different immunotherapies on CNS immunity and gain insights into the pathogenesis of progressive multiple sclerosis. Such in-depth understanding could facilitate individualized and targeted therapies in MS.

While it is not completely resolved if findings in the CSF fully reflect pathological processes in the CNS, several parallel findings in both tissues point into this direction. Clonally expanded CD8\(^+\) T cells are an important hallmark in the CSF of MS patients and are also the dominant infiltrating cell population in the CNS in MS [46, 47]. Additionally, CD8\(^+\) T cell clones can be shared between the brain parenchyma and the CSF [48]. Demyelinating lesions in MS commonly show meningeal infiltration of plasma cells [49] in line with their increase in CSF [11, 14, 43]. Collectively, CSF is likely a suitable surrogate tissue to study the immune cell infiltration of the meninges and the brain parenchyma in inflammatory disorders. Nonetheless, studies with paired samples from CSF, dura, and the CNS in MS would be desirable to substantiate this point.

**Single-cell transcriptomics of the CSF to advance understanding in neurodegenerative disorders and neuro-oncology**

High-dimensional CSF analysis via scRNA-seq has also been successfully employed in neurodegenerative disorders, leptomeningeal tumor metastasis, and neurological infections (Table 1). In a recent study, scRNA-seq was combined with single-cell T cell receptor sequencing (scTCR-seq) to reveal clonally expanded CD8\(^+\) T\(_{EMRA}\) cells in the CSF of AD patients [50], a dementia associated with extracellular β-amyloid and intracellular tau protein deposits in the brain [51]. Intriguingly, CD8\(^+\) T cells were also detected in post-mortem brains of AD patients, especially adjacent to β-amyloid plaques, hippocampi, and nearby leptomeninges [50], indicating that pathogenic CD8\(^+\) T cells enter the brain via the meninges and the CSF and could play a role in the pathophysiology of AD. In a further study, utilizing single-cell transcriptomics of the CSF, the authors detected increased expression of CXCR4 in CD4\(^+\) T cells in patients with Lewy body dementia [52], a dementia characterized by α-synuclein deposits in the brain [53]. Intriguingly, the CSF concentration of CXCL12, ligand of CXCR4, correlated with neuroaxonal damage [52]. Collectively, these novel findings corroborate a decisive role of the immune system in neurodegenerative disorders, which are classically not thought to be immune disorders. Since T\(_{EMRA}\) cells were expanded in AD, their presence in the CSF could support clinicians in the differential diagnosis of dementia in addition to classical neurodegenerative markers (β-amyloid and tau protein). These findings might then pave the way to numerous therapeutic approaches. This is especially relevant because therapeutic options to treat dementia are still limited and therapies targeting specific immune cells are widely used in neuroinflammatory diseases.

By investigating the CSF of patients with leptomeningeal metastases using single-cell transcriptomics, the authors found that cancer cells, but not macrophages, express an iron-binding protein and its receptor [54]. Iron is sparse in the CSF and the iron-binding protein promotes cancer cell growth in the leptomeninges in mice [54]. The cancer cells might thus outcompete macrophages for sparse iron, resulting in a survival advantage [54]. The study serves as a good example of how high-resolution analysis of single CSF cells can pinpoint specific molecules in a complex disease and tissue. In lung cancer, circulating tumor cells in the CSF were deeply characterized with scRNA-seq, which simultaneously resolves cellular composition and expression. The authors detected transcripts of metabolic pathways and cell adhesions, which are required for survival and metastasis of tumor cells [55]. This included complement protein C3, which
is necessary for cancer growth in the leptomeninges [56]. In a case of cancer of unknown primary, the authors identified markers of the CSF tumor cells, which characterized the tumor deeper than conventional immunohistochemistry results and narrowed down its origin [55]. In a different study, patients with brain metastasis of different origins showed identical cytotoxic CD8+ T cell clonotypes in the brain parenchyma and the CSF and selected TCR clones persisted after the therapy [57]. This indicates that the CSF can be used to monitor clonal T cell evolution and potentially guide the therapy in brain metastasis by using identical T cell clones in the CSF to design cell therapies. Furthermore, the findings provide evidence that the CSF is a suitable tissue to study infiltrating immune cells of the brain parenchyma in brain metastasis. This concept is well known in oncology as “liquid biopsy” and not only holds potential to answer scientific questions because of its better accessibility, but also to track resistant clones and detect early relapse in clinical oncology [58]. In primary CNS lymphoma, the analysis of CSF tumor cells displayed substantial heterogeneity within patients [59]. Dissecting the tumor heterogeneity is important because it lays the foundation for identifying malignant therapy-resistant subclones and eventually designing therapeutic protocols targeting resistant cells [58]. In a recent study of melanoma metastases, the authors discovered more dysfunctional T cell proportions in the CSF from patients with leptomeningeal than with brain or skin metastases [60]. Moreover, the CSF of an exceptional therapy responder featured a distinct cellular composition compared to poor responders and showed an increase of functional effector memory T cells after treatment [60]. These findings illustrate how scRNA-seq CSF analysis can be used to better understand treatment response and potentially guide treatment decisions in the future. Collectively, single-cell transcriptomics of CSF cells thus holds diagnostic and prognostic potential in oncology with potential therapeutic implications.

**Single-cell transcriptomics of CSF to study sequelae of COVID-19—the new pandemic?**

In the current COVID-19 pandemic, we and others leveraged scRNA-seq of CSF to investigate the CNS immune response of COVID-19 patients [61, 62]. Since the neurological involvement of COVID-19 is poorly understood and blood does not represent CNS inflammation well, a high-dimensional analysis of the CSF of Neuro-COVID patients was a suitable approach. We observed an expansion of exhausted CD4+ T cells and dedifferentiated monocytes in acute COVID-19 patients with neurological manifestations in the CSF, termed Neuro-COVID [61]. In comparison to viral encephalitis, Neuro-COVID patients showed a less pronounced interferon response that was curtailed in severely affected Neuro-COVID patients [61]. Using scTCR-seq we found evidence for a broad clonal T cell expansion in severe Neuro-COVID patients [61]. Another group reported transcriptional T cell activation, clonal T cell expansion, B cell enrichment, and anti-neuronal autoantibodies in the CSF of Neuro-COVID patients [62]. The findings suggest immune-mediated mechanisms causing damage to the nervous system and provide evidence for investigating immunomodulating treatments in Neuro-COVID. Single-cell transcriptomics of the CSF is therefore suited to dissect the immune response in infectious diseases affecting the CSF. It might also be a powerful tool to investigate long-term post-COVID-19 neurological sequelae.

**Disease monitoring and clinical management of patients based on high-dimensional CSF analysis**

While a detailed knowledge about the cellular and transcriptional landscape of the CSF is of great importance, the ultimate aim of translational research should be to improve patient care. In the field of oncology, recent studies utilized single-cell transcriptomics to predict the clinical outcome. In gastric adenocarcinoma, tumor cells were classified into two subtypes based on their single-cell profile and a strong association with patient survival was observed [63]. The authors of a different study applied scRNA-seq and single-cell protein activity in renal carcinoma and detected a C1Q+TREM2+APOE+ macrophage subpopulation, which was significantly correlated with tumor relapse [64]. Additionally, single-cell transcriptomics was utilized to predict the therapy response in melanoma patients. A CD8+ T cell subpopulation with high levels of oxidative phosphorylation was identified that distinguished immune checkpoint inhibitor responders from non-responders [65]. Similar approaches could be translated to neurology, supporting clinicians in challenging decisions. This includes distinguishing MS from other neuroinflammatory disorders (ONIDs) and predicting the course of illness at an early stage (Fig. 1). Moreover, we envision that findings from high-dimensional CSF analysis could be utilized to train machine learning algorithms to predict the response to individual treatments (Fig. 1). Predictive models bear the advantage that they are capable of using multiple information, such as several abundant cell types and multiple differentially expressed genes, instead of focussing on a single parameter, as it is currently common practice in clinical medicine. Because of the diversity of available immunotherapies in MS [66], tailoring treatments to individual MS patients is especially important. In neurodegenerative disorders like AD, the detection of CD8+ TEMRA cells in the CSF and the brain parenchyma [50]
substantiate existing evidence that immunomodulating therapies might be effective in AD [67, 68]. With limited therapeutic options in AD and trials mostly focussing on β-amyloid, tau, and microglia modulation, T cells could represent an additional promising therapeutic target, illustrating how understanding the CSF can extend therapeutic options in the future.

**High-dimensional CSF analysis in animal models**

The diagnostic value and widespread collection of CSF in human patients contrast sharply with the surprisingly limited information available from animal studies. This might be due to technical challenges in obtaining CSF from the most widely used laboratory species: mice [69]. In addition, the maximum CSF volume collectable from mice is limited to 10–15 μL [69]. Notably, this limited volume has been utilized to study CSF clearance in mice [70]. Moreover, several studies investigated the CSF in rodent AD models [71–73]. Using transgenic mice [71, 72] and rats [73], these studies could provide mechanistic insights, e.g. that β-amyloid pathology causes a biomarker profile observed in AD, even in the absence of tau aggregation and neuronal losses [73]. However, only one study performed a high-dimensional characterization of CSF cells [26]. In this study, we used rats because they provide higher CSF volumes of up to 100–120 μL [74] and consequently higher cell numbers. We still had to pool CSF from 20 rats to achieve a sufficient amount of cells for sequencing [26]. By simultaneously analyzing leukocytes in the brain parenchyma, dura mater, choroid plexus, pia mater, arachnoid, and the CSF, we found unique compositions in each compartment with surprisingly large proportions of B cells in the dura [11]. While animal models additionally often do not translate to humans [75], they permit performing more rigorous mechanistic studies and collecting CNS-associated border compartments more comprehensively. We therefore consider high-dimensional CSF studies in animals a valuable tool, whose potential has not been exploited yet.

**Integrative single-cell analysis in the CSF—opportunities and challenges**

Recent advances in single-cell transcriptomics have led to great opportunities, but also major challenges. It is possible to investigate the transcriptome of thousands or even millions of cells [76] between different diseases, timepoints, and tissues to answer scientific and clinical relevant questions that could not have been addressed previously. However, there are several issues related to single-cell transcriptomics summarized in Table 2. Due to a low starting amount, transcripts can be missed during reverse transcription, which leads to “dropout” events, the presence of a gene at moderate/high expression in one cell but absence in another cell [77]. Consequently, the gene coverage of most scRNA-seq platforms is limited so that genes that are expressed at lower levels but are biologically important can be missed. Complex distributions of transcript abundances have led to an ongoing discussion about the optimal normalization method [78]. Moreover, there are around 170 integration tools available for scRNA-seq [79]. The most popular integration tools have recently been benchmarked [80] to assess their performance in removing batch effects, unwanted technical variation, while conserving biological variation. Nonetheless, it remains a challenge to identify the most appropriate tool and settings as each dataset requires individual settings. While this problem has already been tackled in integrative scRNA-seq studies of CSF and blood [81, 82], it will become even more challenging in

| Table 2 | Advantages and drawbacks of scRNA-seq of the CSF |
|---|---|
| **Advantages** | **Drawbacks** |
| Hypothesis-free in-depth characterization of cell populations [41] | Due to a low starting amount, transcripts can be missed during reverse transcription (“dropouts”), leading to a limited gene coverage [77] |
| Detection of novel disease- and cell-type-specific biomarkers Can be combined with published CSF datasets to increase statistical power or non-CSF datasets to compare cell abundances or phenotypes between compartments, which improves the reproducibility across studies | False positive and false negative DE genes can lead to false discoveries [98] |
| Wide range of analyses possible with a plethora of computation tools [100] Because of limited CSF cell counts, deep-sequencing of CSF cells is affordable | Batch effect can be misinterpreted as novel biological findings while correction of batch effects entails the risk of removing biological variation [80, 99] |
| Increasingly multi-dimensional data collected simultaneously (proteome, transcriptome, epigenome) | Analyses remain mostly descriptive and cannot substitute mechanistic experiments [101] |
| Number of total available cells by limited low CSF cell counts, thus relative cell frequencies can be biased and rare cell populations might be completely missed | Number of total available cells by limited low CSF cell counts, thus relative cell frequencies can be biased and rare cell populations might be completely missed |
| Because of limited CSF cell counts, differential expression of rare cell populations between conditions can be unreliable [102] | |

---

Heming et al. Genome Medicine (2022) 14:94
Very recently a method has been introduced that coupled cells processed with CITE-seq was published [90]. The well-annotated human peripheral blood mononuclear cells, processed with staining procedures limits the applicability of CITE-seq/REAP-seq in CSF cells, which are naturally limited in number. The single-cell assay for transposase-accessible chromatin by sequencing (scATAC-seq) permits epigenomic profiling, thus revealing gene regulatory programs, e.g. detecting a regulatory network that governs exhaustion in tumor-infiltrating T cells [86]. Several approaches have been developed in the last years that combine scRNA-seq and scATAC-seq [87, 88]. Very recently a method has been introduced that couples cell surface and intracellular proteins with scATAC-seq (ASAP-seq) [89] and even an approach that enables measuring gene expression, chromatin accessibility, and protein in the same cell (DOGMA-seq) [89]. At the same time, computational tools were developed that allow the integration of multi-omics data in a weighted analysis [90]. Such a joint weighted analysis enables one data modality to compensate for the weakness of another, resulting in a higher resolution of cellular heterogeneity and a more holistic understanding. For example, T cells often form a phenotypic gradient in scRNA-seq [11] and the combination with protein data enables a better separation of T cell states [90]. Since T cells dominate the CSF, we assume that CSF analysis will benefit from multi-omics approaches. The resulting higher resolution will dissect the immune cells in the CSF more precisely than current methods. We believe that the use of multi-omics in combination with higher sample numbers can lead to a refined disease subtype classification in complex neurological diseases, such as MS and inflammatory polyneuropathies.

Towards future atlas initiatives in the CSF realm
The number of cells in single-cell datasets is steadily growing and single-cell atlases are being generated. Recently, a large reference atlas of over 200,000 well-annotated human peripheral blood mononuclear cells processed with CITE-seq was published [90]. The Tabula Sapiens is a single-cell transcriptomic atlas of nearly 500,000 annotated human cells from 24 tissues and organs [91]. The Human Cell Atlas bundles atlas initiatives with the aim to identify the molecular profile of every human cell type with scRNA-seq and single-cell multi-omics as key technologies [92]. Most single-cell transcriptomics datasets of the CSF are relatively small so far (Table 1). We believe that the generation of a large reference atlas of CSF cells will necessitate establishing multicenter collaborations, optimally preserving CSF cells across centers, integrating existing datasets, and making the resulting annotated datasets publicly available, including an interactive visualization. A protocol for the cryopreservation of CSF has recently been published, which showed high post-thaw viability [93]. However, cell loss in CSF cryopreservation is a major concern given the low cell concentration and the limited volume of CSF. On the other hand, cryopreserved samples are well suited for multiplexing, either via cell hashing [94] or natural genetic variations [95, 96], which considerably reduces batch effects costs and experimental work. Data integration is a major challenge, but lessons can be learned from the existing large consortia. CSF atlases should be integrated into preexistent multitissue atlases, such as the Tabula Sapiens, because this enables direct comparisons between cells of different tissues. We believe that further and larger single-cell transcriptomics studies of the CSF will be extremely valuable to better understand neuro-immunological responses and neurological diseases in general.

Conclusions
While CSF analysis has played an important role in clinical neurology for decades, recent high-dimensional methods, such as single-cell transcriptomics, are capable of exploring the CSF at unprecedented resolution. The meninges, filled with the CSF, have thus been identified as a neuroimmunological interface. Single-cell transcriptomics studies of the CSF have dissected the immune response in complex neurological diseases, including inflammatory, degenerative, infectious, and oncological CNS disorders. Important next steps will be to increase the number of samples by multi-center collaborations and integrate multi-omics approaches. This requires improved cell preservation methods, which is currently still hampered by cell loss, particularly with low CSF cells count, and careful bioinformatic analysis to tackle batch effects between individuals, tissues, and modalities. We envision that high-dimensional techniques like single-cell transcriptomics will be increasingly applied in challenging differential diagnosis, individualized prognosis, and prediction of therapy response.
Abbreviations

AD Alzheimer's disease
AIE Autoimmune encephalitis
APC Antigen-presenting cells
CNS Central nervous system
CSF Cerebrospinal fluid
LP Lumbar puncture
MS Multiple sclerosis
MOG Myelin oligodendrocyte glycoprotein
ONID Other neuroinflammatory disorders
scRNA-seq Single-cell RNA sequencing
scTCR/BCR-seq Single-cell T/B cell receptor sequencing
TEFARA T effector memory cells expressing CD45RA
TFH T follicular helper cells

Authors' contributions

M.H. and G.M.z.H. wrote the review. G.M.z.H. and H.W. conceived the concept and approved its final version.

Funding

G.M.z.H. was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) grant number ME4050/13-1, and grant number ME4050/8-1, under the G.M.z.H. was supported by grants from the Deutsche Forschungsgemeinschaft and approved its final version.

TFH               T follicular helper cells

Authors' contributions

M.H. and G.M.z.H. wrote the review. G.M.z.H. and H.W. conceived the concept and approved its final version.

Funding

G.M.z.H. was supported by grants from the Deutsche Forschungsgemeinschaft (DFG) grant number ME4050/13-1, and the Heisenberg program of the DFG (grant number ME4050/13-1), and grant number ME4050/8-1, under the frame of E-Rare-3, the ERA-Net for Research on Rare Diseases. M. Heming and G.M.z.H. were supported by the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster (grant MzH3/020/20 to G.M.z.H. and M. Heming). The funders had no role in designing the study, collection, analysis, and interpretation of the data or writing the manuscript. Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

G.M.z.H. received compensation for serving on scientific advisory boards (Alexion) and speaker honoraria (Alexion). H.W. is acting as a paid consultant for AbbVie, Actelion, Biogen, IGEIS, Johnson & Johnson, Novartis, Roche, Sanofi-Aventis, and the Swiss Multiple Sclerosis Society. The remaining authors declare that they have no competing interests.

Received: 31 January 2022   Accepted: 28 July 2022
Published online: 17 August 2022

References

1. Raper D, Louveau A, Kipnis J. How do meningeal lymphatic vessels drain the CNS? Trends Neurosci. 2016;39:581–6.
2. Ahn JH, Cho H, Kim J-H, Kim SH, Harn J-S, Park I, et al. Meningeal lymphatic vessels at the skull base drain cerebrospinal fluid. Nature. 2019;572:62–6.
3. Rustenhouven J, Driew U, Mamuladze T, de Lima KA, Dykstra T, Wall M, et al. Functional characterization of the dural sinuses as a neuroimmune interface. Cell. 2018;174:1000–1016.e27.
4. Ifill JJ, Wang M, Lao Y, Plogg BA, Peng W, Guenderson GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4:147ra111.
5. Johnson DR, O’Neill BP, Decker PA, Kosel ML, Lanzino G, Hammack JE. Mortality and discharge to home after closed brain biopsy: analysis of 3523 cases from the State of California, 2003-2009. World Neurosurg. 2013;79:110–5.
6. Warren JD, Schott JM, Fox NC, Thom M, Revesz T, Holton JL, et al. Brain biopsy in dementia. Brain. 2005;128(Pt 9):196–25.
7. Barker FG, Curry WT, Carter BS. Surgery for primary supratentorial brain tumors in the United States, 1988 to 2000: the effect of provider case-volume and centralization of care. Neuro-Oncology. 2005;7:49–63.
8. Wright BLC, Lai JTF, Sinclair AJ. Cerebrospinal fluid and lumbar puncture: a practical review. J Neurol. 2012;259:1530–45.
9. Han S, Lin YC, Wu T, Salgado AD, Mnehjati I, Wuest SC, et al. Comprehensive immunophenotyping of cerebrospinal fluid cells in patients with neuromyelitis optica disorders. J Neurol. 2014;192:2561–63.
10. de Graaf MT, Smitt PAE, Luijtwiel RL, van Velzen C, van den Broek PDM, Kraan J, et al. Central memory CD4+ T cells dominate the normal cerebrospinal fluid. Cytometry B Clin Cytom. 2011;80:43–50.
11. Schafflick D, Xu CA, Hartlehnert M, Cole M, Schulte-Mecklenbeck A, Lauwein T, et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis.Nat Commun. 2020;11:247.
12. Esaulova E, Cantonii C, Shchukina I, Zaitsev K, Bucelli RC, Wu GF, et al. Single-cell RNA-seq analysis of human CSF microglia and myeloid cells in neuromyelitis optica. Neuroil Neuroimunol Neuroinfiamm. 2020;7.
13. Farhadian SF, Mehta SS, Zagrofu C, Robertson K, Price RW, Pappalardo J, et al. Single-cell RNA sequencing reveals microglia-like cells in cerebrospinal fluid during virolologically suppressed HIV. JCI. Insights. 2018;3.
14. Ramesh A, Schubert RD, Greenfield AL, Dandekar R, Loudermilk R, Sabatin Jj, et al. A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proc Natl Acad Sci U S A. 2020;117:22932–43.
15. Roostaei T, Daconou C, Touil H, Harbison C, Zhang Y, Epstein S, et al. Defining the architecture of cerebrospinal fluid cellular communities in neuromyelitis optica diseases. BioRxiv. 2021.
16. Ginhoux F, Greter M, Leboreuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science. 2013;330:841–5.
17. Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Fassdugo EG, et al. Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways. Nat Neurosci. 2013;16:273–80.
18. Pappalardo J, Zhang L, Pecsk M, Kretz O, Zargrafou C, Raddassi K, et al. Transcriptomic and clonal characterisation of T cells in the human central nervous system. Sci Immunol. 2020;5.
19. RansohoffRM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Rev Neurol. 2012;162:25–35.
20. Dodd KC, Emsley HCA, Desborough MJR, Chhetri SK. Periprocedural infection in the central nervous system: a practical review. J Neurol. 2012;259:1530–45.
21. Frederiks JA, Koehler PJ. The first lumbar puncture. J Hist Neurosci. 1997;6:147–53.
22. Deisenhammer F, Bartos A, Egg R, Gilhus NE, Giovannoni G, Rauer S, et al. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol. 2006;13:913–22.
23. Thompson AJ, Banwell BL, Barkhof F, Carrell WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–73.
24. Alves de Lima K, Rustenhouven J, Kipnis J. Meningeal immunity and its function in maintenance of the central nervous system in health and disease. Annu Rev Immunol. 2020;38:597–620.
25. Fitzpatrick Z, Frazer G, Ferro A, Clare S, Bouladoux N, Ferdinand J, et al. Gut-educated IgA plasma cells defend the meningeal venous sinuses. Nature. 2020;587:472–6.
26. Schafflick D, Wolbert J, Heming M, Thomas C, Hartlehnert M, Börsch A-L, et al. Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meningi. Nat Neurosci. 2021;24:1215–24.
27. Brioschi S, Wang W-L, Peng V, Wang M, Shchukina I, Greenberg ZJ, et al. Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders. Science. 2021.
28. Wang Y, Chen D, Xu D, Huang C, Xing R, He D, et al. Early developing B cells undergo negative selection by central nervous system-specific antigens in the meninges. Immunity. 2021;54:2784–2794.e6.
29. Cugurra A, Mamuladze T, Rustenhouven J, Dykstra T, Berosthili G, Greenberg ZJ, et al. Skull and vertebral bone marrow are myeloid cell reservoirs for the meninges and CNS parenchyma. Science. 2021;373.
30. Puloue FE, Cruz-Hernández JC, Yang C, Kaya Z, Paccalet A, Wojtkeiwicz G, et al. Cerebrospinal fluid can exit into the skull bone marrow and instruct cranial hematopoiesis in mice with bacterial meningitis. Nat Neurosci. 2022;25:567–76.

31. Hsu M, Laaker C, Madrid A, Herbst M, Choy YH, Sandor M, et al. Neuroinflammation creates an immune regulatory niche at the meningeal vascular surface near the cribriform plate. Nat Immunol. 2022;23:581–93.

32. Louveau A, Herz J, Alme MN, Salvador AF, Dong MQ, Viar KE, et al. CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature. Nat Neurosci. 2018;21:380–91.

33. Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, et al. Meningeal lymphatics affect microglia responses and anti-AB immunotherapy. Nature. 2021;593:255–60.

34. Albayram MS, Smith G, Tufan F, Tuna IS, BostanciKılısgöl M, Zile M, et al. Non-invasive MR imaging of human brain lymphatic networks with connections to cervical lymph nodes. Nat Commun. 2022;13:203.

35. Jacob L, de Brito NJ, Lenck S, Corcy C, Benbelkacem F, Geraldo LHM, et al. 3D-imaging reveals conserved cerebrospinal fluid drainage via meningeal lymphatic vasculature in mice and humans. BioRxiv. 2022.

36. Hartlehnert M, Börsch A-L, Li X, Burmeister M, Gerwen H, Schaffick D, et al. Bc6 controls meningeal Th17-B cell interaction in murine neuroinflammation. Proc Natl Acad Sci U S A. 2021;118.

37. Method of the year 2013. Nat Methods. 2014;11:1.

38. Papalexi E, Satija R. Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2018;18:35–45.

39. Horste MZ, G, Gross CC, Klotz L, Schwab N, Wiendl H. Next-Generation sequencing in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A. 2020;117:22930–8.

40. Svensson V, Veito-Tormo R, Teichmann SA. Exponential scaling of single-cell RNA-seq in the past decade. Nat Protoc. 2018;13:599–604.

41. Patil VS, Madrigal A, Schmiedel BJ, Clarke J, O’Rourke P, de Silva AD, et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 2021;184:2988–3005.e16.

42. Li C, Pooon YP, Karlinsky K, Tian YF, Thapaliya S, Thongkum A, et al. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. J Exp Med. 2022;219.

43. Schirmer L, Velmeshev D, Holmqvist S, Kaufmann M, Werneburg S, Jung G, et al. Cerebrospinal fluid can exit into the skull bone marrow and instruct cranial hematopoiesis in mice with bacterial meningitis. Nat Neurosci. 2022;25:567–76.

44. Ruan H, Wang Z, Zhai Y, Xu P, Li, Zheng J, et al. Single-cell transcriptome analysis of diffuse large B cells in cerebrospinal fluid of central nervous system lymphoma. Sci. 2021;374:102972.

45. Smalley J, Chen Z, Phadke M, Li J, Xu Y, Wyatt C, et al. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Cell. 2021;27:4109–25.

46. Heming M, Li X, Räuber S, Mausberg AK, Börsch A-L, Hartlehnert M, et al. Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Differentially Monocyties in Cerebrospinal Fluid. Immunity. 2021;54:164–75.

47. Song E, Bartley CM, Chow RD, Ngo TT, Jiang R, Zamecnik CR, et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. Cell Rep Med. 2021;2:100288.

48. Wang R, Dang M, Harada K, Han G, Wang F, Pool Pizzi M, et al. Single-cell dissection of intratumor heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nat Med. 2021;27:141–51.

49. Obraudovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 2021;184:2988–3005.e16.

50. Li C, Pooon YP, Karlinsky K, Tian YF, Thapaliya S, Thongkum A, et al. A high OXPHOS CD8 T cell subset is predictive of immunotherapy resistance in melanoma patients. J Exp Med. 2022;219.

51. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: A review. JAMA. 2021;325:766–79.

52. Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019;51:404–13.

53. Kim K, Wang X, Ragonaard E, Bodogai M, Illouz D, DeLuca M, et al. Therapeutic B-cell depletion reverses progression of Alzheimer’s disease. Nat Commun. 2021;12:2185.

54. Lim NK-H, Moestrup V, Zhang X, Wang W-A, Moller A, Huang F-D. An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice. J Vis Exp. 2018.

55. Xu H, Fame RM, Sadegh C, Sutin J, Naranjo C, Syau D, et al. Choroid plexus NKCC1 mediates cerebrospinal fluid clearance during mouse early postnatal development. Nat Commun. 2022;13:2447.

56. Liu L, Herukka S-K, Minkevičiene R, van Grooten T, Tanila H. Longitudinal observation on CSF Abeta42 levels in young to middle-aged amyloid precursor protein/presenilin-1 doubly transgenic mice. Neurobiol Dis. 2004;17:516–23.

57. Schellie J, Hänel LM, Gopfert JC, Joos TO, Vanderstichele H, Stoops E, et al. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimers Dement. 2017;13:701–9.

58. Parent MJ, Zimmer ER, Shin M, Kang MS, Fonov VS, Mathieu A, et al. Multimodal imaging in rat model recapitulates Alzheimer’s disease biomarkers abnormalities. J Neurosci. 2017;37:12263–71.

59. Nigro P, Rijkersdike V, Mudigonda K, Bhayrapuneni G, Mudadda N, Saralaya R, et al. A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system. J Neurosci Methods. 2009;178:116–9.
75. Hackam DG, Redelmeier DA. Translation of research evidence from animals to humans. JAMA. 2006;296:1731–2.

76. Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566:496–502.

77. Kharchenko PV, Silberstein L, Scadden DT. Bayesian approach to single-cell differential expression analysis. Nat Methods. 2014;11:740–2.

78. Choudhary S, Satija R. Comparison and evaluation of statistical error models for scRNA-seq. Genome Biol. 2022;23:27.

79. Zappia L, Phipson B, Oshlack A. Exploring the single-cell RNA-seq analysis landscape with the scRNA-tools database. PLoS Comput Biol. 2018;14:e1006245.

80. Luecken MD, Büttner M, Chaichoompu K, Danese A, Interlandi M, Mueller MF, et al. Benchmarking atlas-level data integration in single-cell genomics. Nat Methods. 2022;19:1843–51.

81. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16:1289–96.

82. Lopez R, Regier J, Cole MB, Jordan M, Yosef N. Deep generative modeling for single-cell transcriptomics. Nat Methods. 2018;15:1053–8.

83. Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al. Comprehensive Integration of Single-Cell Data. Cell. 2019;177:1888–1902.e21.

84. Fairclough OR, Abdullayev I, Hagemann‑Jensen M, Schell JP, Lanner F, Sandberg R. Single-cell sequencing of the small-RNA transcriptome. Nat Biotechnol. 2016;34:1264–6.

85. Stoeckius M, Hafemeister C, Stephanow W, Houck-Loomis B, Chattopadhyay PK, Swedlow H, et al. Simultaneous epistle and transcriptome measurement in single cells. Nat Methods. 2017;14:865–8.

86. Satpathy AT, Granja JM, Yost KE, Qi Y, Meschi F, McDermott GP, et al. Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion. Nat Biotechnol. 2019;37:925–36.

87. Chen S, Lake BB, Zhang K. High-throughput sequencing of the transcriptome and chromatin accessibility in the same cell. Nat Biotechnol. 2019;37:1452–7.

88. Ma S, Zhang B, LaFave LM, Earl AS, Chiang Z, Hu Y, et al. Chromatin Potential Identified by Shared Single-Cell Profiling of RNA and Chromatin. Cell. 2020;183:1103–1116.e20.

89. Mimitou EP, Lareau CA, Chen KY, Zorzetto-Fernandes AL, Hao Y, Take-shima Y, et al. Scalable, multimodal profiling of chromatin accessibility, gene expression and protein levels in single cells. Nat Biotechnol. 2021;39:1246–58.

90. Hao Y, Hsu S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, et al. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573–3587.e29.

91. The Tabula Sapiens Consortium, Quake SR. The Tabula Sapiens: a single cell transcriptomic atlas of multiple organs from individual human donors. BioRxiv. 2021.

92. Regev A, Teichmann SA, Lander ES, Amit I, Benoist C, Birney E, et al. The human cell atlas. eLife. 2017;6.

93. Oh H, Leventhal O, Channappa D, Henderson VW, Wyss-Coray T, Lehaller B, et al. Methods to investigate intrathecal adaptive immunity in neurodegeneration. Mol Neurodegener. 2021;16:3.

94. Stoeckius M, Zheng H, Houck-Loomis B, Hao S, Yeung BZ, Mauck WM, et al. Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single-cell genomics. Genome Biol. 2018;19:224.

95. Kang HM, Subramaniam M, Tang S, Nguyen M, Maliskova L, McCarthy E, et al. Multiplexed droplet single-cell RNA-sequencing using natural genetic variation. Nat Biotechnol. 2018;36:89–94.

96. Huizing J, McCarthy DJ, Stige O, Vireo L. Bayesian demultiplexing of pooled single-cell RNA-seq data without genotype reference. Genome Biol. 2019;20:273.

97. Friedrich M, Kehl N, Engelke N, Kraus J, Lindner K, Münch P, et al. Intrathelial activation of CDB4+ memory T cells in IgG4-related disease of the brain parenchyma. EMBO Mol Med. 2021;13:e13953.

98. Squar JW, Gautier M, Keshet C, Anderson MA, James ND, Hutson TH, et al. Confronting false discoveries in single-cell differential expression. Nat Commun. 2021;12:5692.